NCT05379595 2026-04-13
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
Clinical Trials
38 trialsNCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT05846867 2026-03-04
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Phase 1/2 Active not recruiting
NCT04421820 2026-01-27
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07365592 2026-01-26
Neo-CD
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT06385925 2025-12-15
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2 Recruiting
NCT05627635 2025-11-10
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT03564912 2021-08-25
Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC
Zhejiang University
Phase 1/2 Completed
NCT02244632 2020-09-09
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
Isofol Medical AB
Phase 1/2 Completed
NCT04380103 2020-05-08
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT01193517 2020-04-15
Azacitidine and CAPOX in Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04008511 2019-07-05
Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
China Medical University, China
Phase 1/2 Unknown
NCT00004187 2019-06-26
Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
Swiss Cancer Institute
Phase 1/2 Completed
NCT01975454 2018-04-19
Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer
Shanghai University of Traditional Chinese Medicine
Phase 1/2 Completed
NCT01047293 2017-04-04
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
University of Utah
Phase 1/2 Completed
NCT00244348 2015-08-27
Hepatic Artery Infusion With Oxaliplatin
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT01110941 2015-05-19
SCI-101
Peking University
Phase 1/2 Completed
NCT00494221 2014-03-27
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
Phase 1/2 Completed
NCT00819754 2014-01-14
IXO+A
Ottawa Hospital Research Institute
Phase 1/2 Terminated
NCT00026299 2013-09-05
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
University of Chicago
Phase 1/2 Completed
NCT00049101 2013-06-24
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00086931 2013-03-08
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT00087334 2013-02-01
Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00784446 2013-01-07
First-line Therapy of Stage IV Colorectal Cancer
University of Cologne
Phase 1/2 Completed
NCT00055822 2012-07-04
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT00217711 2012-06-05
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Swiss Cancer Institute
Phase 1/2 Completed
NCT01016639 2011-10-17
CORGI
Lund University Hospital
Phase 1/2 Completed
NCT00005050 2011-03-28
Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer
NYU Langone Health
Phase 1/2 Completed
NCT00345761 2010-08-16
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
Chugai Pharmaceutical
Phase 1/2 Completed
NCT00496704 2009-08-21
Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00531245 2009-07-02
A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer
Samsung Medical Center
Phase 1/2 Completed
NCT00524706 2008-11-13
Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer
Shizuoka Cancer Center
Phase 1/2 Unknown